Zobrazeno 1 - 10
of 702
pro vyhledávání: ''
Autor:
Peter Malfertheiner, Alexander Stein, Ingo Tamm, Salah-Eddin Al-Batran, PaFLO investigators, Anica Högner, Nils Homann, Axel Hinke, Kirstin Breithaupt, Jens T. Siveke, Dietrich Gläser, Peter C. Thuss-Patience, Prisca Bartels, Mario Lorenz, Arndt Vogel
Publikováno v:
International Journal of Cancer. 150:1007-1017
VEGF inhibition in gastric cancer has a proven benefit in the second line setting. Pazopanib, an oral tyrosine kinase inhibitor, selectively inhibits VEGFR-1, -2 and -3, c-kit and PDGF-R resulting in inhibition of angiogenesis. This open-label random
Autor:
Marco Pavesi, Moisés Mira Flores, Aurea Duran, Josep Gumà, Alessandra Pranzo, Alexis Serikoff, Bernard Rappe, Angus Robinson, Serena Hilman, Benoit Baron, Louis-Marie Dourthe, D. Mott, Steven Joniau, M. Herdman, Stéphane Mallick, Roberto Bordonaro, Maria De Santis, Ugo De Giorgi, Heather Payne
Publikováno v:
International Journal of Cancer. 150:837-846
In randomized clinical trials, the androgen-receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC). This study captured efficacy, safety and patient-reported outcomes (PROs) of
Autor:
Gangling Zhang, Min-Yi Cheng, Mei Yang, Ci-Qiu Yang, Jie Li, Yin Cao, Teng Zhu, Hong-Fei Gao, Ying Lin, Zhenzhen Liu, Zhi-Yong Wu, Fei Ji, Jieqing Li, Kun Wang, Liulu Zhang
Publikováno v:
International Journal of Cancer. 150:654-662
Previous studies have shown that the addition of carboplatin to neoadjuvant chemotherapy improved the pathologic complete response (pCR) rate in patients suffering from triple-negative breast cancer (TNBC), and patients who obtained a pCR could achie
Autor:
Osvaldo Espin-Garcia, Geoffrey Liu, Kouros Owzar, Maura N Dickler, Monica M. Bertagnolli, Danyu Lin, Chen Jiang, Amy S. Etheridge, Federico Innocenti, Alan P. Venook, Heinz-Josef Lenz, Hedy L. Kindler, Mark J. Ratain, Jin Wang, Alexander B. Sibley, Wei Xu, Julia C F Quintanilha
Publikováno v:
Int J Cancer
Germline variants might predict cancer progression. Bevacizumab improves overall survival (OS) in patients with advanced cancers. No biomarkers are available to identify patients that benefit from bevacizumab. A meta-analysis of genome-wide associati
Autor:
Xiaojing Zhang, Zhiqiang Meng, Shanzhi Gu, Shukui Qin, Zhendong Chen, Xiao Zhang, Linna Wang, Xinni Chen, Jianjun Zou, Ying Liu, Jianping Xiong, Zhenggang Ren
Publikováno v:
International Journal of Cancer. 149:1944-1954
Biliary tract cancer (BTC) is a highly malignant tumor with limited treatment options and poor prognosis. Our study aimed to evaluate camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced BTC. In this multicenter, open-l
Autor:
Mohammad Ghasemi, Andrew Goey, John Wilton, Wiam Bshara, Adrienne Groman, Renuka Iyer, Christos Fountzilas, Wen Wee Ma, Mateusz Opyrchal, Alex A. Adjei, Rachel Evans, Kristopher Attwood
Publikováno v:
Int J Cancer
In this phase I, dose-escalation study, we sought to determine the maximum tolerated dose (MTD) of the anaplastic lymphoma kinase/c-ROS oncogene 1 receptor (ALK/ROS1) inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients
Autor:
Christopher Wills, Katie Watts, Victoria Gray, Valentina Escott-Price, David J. Kerr, Hannah West, Claire Palles, Richard Kaplan, Nada Al-Tassan, Ayman Madi, Tim Maughan, Rachel Kerr, Jeremy Peter Cheadle, Richard S. Houlston
Publikováno v:
International Journal of Cancer. 149:1713-1722
Chemotherapies administered at normal therapeutic dosages can cause significant side-effects and may result in early treatment discontinuation. Inter-individual variation in toxicity highlights the need for biomarkers to personalise treatment. We sou
Autor:
Markus Moehler, Laura Elisabeth Fischer, Jobst Christian von Einem, Laura Schlieker, Florian Kaiser, A. Stahler, Andreas Jung, Ivan Jelas, Dominik Paul Modest, Alexander Kiani, Ludwig Fischer von Weikersthal, Thomas Decker, Sebastian Stintzing, Kathrin Heinrich, Julian Walter Holch, Thomas Kirchner, Volker Heinemann, Christoph B. Westphalen, Annabel Helga Sophie Alig, Lena Weiss
Publikováno v:
International Journal of Cancer. 149:1935-1943
Secondary resection of metastases is recommended in metastatic colorectal cancer (mCRC). Data describing changes in mutational profiles of corresponding primary tumor and metastatic tissue after conversion treatment are limited. Next generation seque
Autor:
Viktor Umansky, Juliane Poelchen, Jochen Utikal, Karol Granados, Marlene Vierthaler, Laura Hüser, Tamara Steinfass, Qian Sun, Huizi Wu, Ke Liu, Aniello Federico, Daniel Novak
Publikováno v:
International Journal of Cancer. 149:657-674
Metastatic melanoma is an aggressive skin cancer and associated with a poor prognosis. In clinical terms, targeted therapy is one of the most important treatments for patients with BRAFV600E -mutated advanced melanoma. However, the development of res
Autor:
Satoru Kikuchi, Hiroshi Tazawa, Toshiaki Ohara, Yasuhiro Shirakawa, Kazuhiro Noma, Hiroaki Sato, Toru Narusaka, Takuya Kato, Akihiro Matsukawa, Toshiyoshi Fujiwara, Yuki Katsura, Noriyuki Nishiwaki, Yasuko Tomono
Publikováno v:
International Journal of Cancer. 149:347-357
Esophageal cancer is a disease showing poor prognosis. Although combination chemotherapy using cisplatin (CDDP) and 5-fluorouracil is standard for unresectable esophageal cancer, the response rate is 35%. Cancer stem cells (CSCs) and inflammation are